Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-033 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NHV Cohorts: ARO-033 | EXPERIMENTAL | Participants will receive either a single dose of ARO-033 on Day 1 (single-ascending dose \[SAD\]) or 2 doses (multiple-ascending dose \[MAD\]) of ARO-033 administered on Day 1 and Day 29. |
| NHV Cohorts: Placebo | PLACEBO_COMPARATOR | Participants will receive either a single dose of placebo on Day 1 (SAD) or 2 doses (MAD) of placebo administered on Day 1 and Day 29. |
| AMD Cohorts: ARO-033 | EXPERIMENTAL | Participants will receive up to 5 doses of ARO-033. |
| AMD Cohorts: Placebo | PLACEBO_COMPARATOR | Participants will receive up to 5 doses of placebo. |
| Name | Type | Description |
|---|---|---|
| ARO-033 | DRUG | ARO-033 will be administered as a subcutaneous (SC) injection per schedule specified in the arm description. |
| Placebo | DRUG | Placebo matching to ARO-033 will be administered as SC injection per schedule specified in the arm description. |
Key Inclusion Criteria: * NHV cohorts only: Adults 18 to 65 years of age who are not pregnant, not breastfeeding, and do not plan to become pregnant (or impregnate their partners) during the study and for at least 90 days following the end of the study. * AMD cohorts only: Adults ≥50 years of age w...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE2 | Iptacopan, GT005, FWY003 |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Hoffmann-La Roche | RHHBY | 10 | PHASE3 | Ranibizumab, Susvimo, RO7965032, OpRegen, Faricimab |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 938, Aflibercept |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Ocugen Inc | OCGN | 1 | PHASE3 | OCU410 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-033 |
| Bayer | BAYRY | 2 | - | Aflibercept |
ARO-033 is an investigational small molecule being developed by Arrowhead Pharmaceuticals, Inc. for age-related macular degeneration. It is in Phase 1 clinical development and has not been approved by the FDA. It is being studied in a first-in-human trial that is currently recruiting participants.
ARO-033 is being developed as a treatment for age-related macular degeneration, a condition affecting the macula that can lead to vision loss. The drug is in Phase 1 testing, so its use remains investigational. Its first-in-human study is enrolling adults, including healthy volunteers, in New Zealand.
ARO-033 is being developed by Arrowhead Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ARWR. The company is the sponsor of the first-in-human study of ARO-033 in adult participants. Arrowhead is a biopharmaceutical company focused on developing medicines that treat disease by silencing specific genes.
ARO-033 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 program consists of a single first-in-human study that is currently recruiting, with no completed trials reported to date. The study is randomized, double-blind, and placebo-controlled.
ARO-033 is being evaluated in one clinical trial, NCT07662096, titled A First-In-Human Study of ARO-033 in Adult Participants. The Phase 1 study is recruiting and plans to enroll 84 participants with age-related macular degeneration. It is randomized, double-blind, and placebo-controlled, and it is being conducted in New Zealand.